Hiroki Izumi

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip et al. · New England Journal of Medicine · 2023 · 390 citations

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai et al. · Journal of Clinical Oncology · 2023 · 250 citations · Full text

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Yukie Kashima, Daisuke Shibahara, Ayako Suzuki et al. · Cancer Research · 2021 · 102 citations · Full text

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Hiroki Izumi, Shingo Matsumoto, Jie Liu et al. · Nature · 2021 · 68 citations · Full text

Oncogenic Agent, Medicine, Non‐small‐cell Lung Cancer +10

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1

Toshinori Ando, Nadia Arang, Zhiyong Wang et al. · Communications Biology · 2021 · 60 citations · Full text